BACKGROUND/AIM:High-dose methotrexate (HD-MTX) is pivotal chemotherapy in the treatment of patients with osteosarcoma. Blood concentrations of MTX are associated with several side effects, but there are large individual differences in the elimination of MTX. The aim of this study was to explore risk factors for delayed elimination of MTX in children, adolescents and young adults with osteosarcoma.PATIENTS AND METHODS:We conducted a retrospective study on Japanese patients with osteosarcoma who were treated with HD-MTX at Kanazawa University Hospital from April 2006 to March 2015. Risk factors for delayed elimination of methotrexate were identified by multiple logistic regression analysis.RESULTS:A total of 92 cycles of HD-MTX therapy were analyzed. Female and lower creatinine clearance (CCr) were identified as independent risk factors for delayed elimination of MTX.CONCLUSION:Knowing the factors associated with delayed elimination of MTX could lead to safer and optimized chemotherapy for patients with osteosarcoma.Copyright? 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
展开▼
机译：背景/目的：高剂量甲氨蝶呤（HD-MTX）是治疗骨肉瘤患者的枢转化疗。 MTX的血液浓度与几个副作用有关，但在消除MTX中存在大的个体差异。本研究的目的是探讨用骨肉瘤的儿童，青少年和年轻成人延迟消除MTX的危险因素：我们对日本患者进行了回顾性研究，患者在Kanazawa大学医院接受了HD-MTX治疗的骨肉瘤患者从2006年4月到2015年3月。通过多元逻辑回归分析鉴定出延迟消除甲氨蝶呤的危险因素。结果：分析了总共92个HD-MTX治疗循环。将雌性和降低肌酐清除（CCR）被确定为延迟消除MTX的独立危险因素。结论：知道与延迟消除MTX相关的因素可能导致骨肉瘤患者的更安全和优化的化疗吗？ 2020年，国际抗癌研究所（George J. Delinasios博士），保留所有权利。
展开▼
